Gland Pharma Limited has reported strong financial results for Q4 FY26, achieving a 22% year-over-year increase in revenue from operations to ₹17,428 million. The company saw robust performance in its base business, with significant milestones in R&D, new product launches, and continued expansion of its Cenexi operations in Europe. The Board has also recommended a final dividend of ₹20 per equity share for the full fiscal year.
Consolidated Financial Performance
For the quarter ending March 31, 2026, Gland Pharma demonstrated strong growth across key metrics. Total revenue reached ₹17,428 million, marking a 22% increase compared to the same period last year. Gross profit for the quarter stood at ₹11,515 million with a stable margin of 66%. The company’s adjusted EBITDA also saw substantial growth, rising 51% year-over-year to reach ₹5,244 million.
Base Business and R&D Milestones
The company’s base business generated ₹12,648 million in revenue, representing a 22% year-over-year growth. A key driver for this performance was the strategic focus on complex product development. During the quarter, the company filed eight ANDAs and received 11 approvals, contributing to a cumulative total of 337 U.S. approvals. Additionally, the company successfully launched five new molecules in the USA, including Dalbavancin and Brimonidine, during the quarter.
Strategic Updates and Expansion
The Cenexi business continued its positive momentum, supported by production ramp-ups in an inactivated vaccine and a sterile ophthalmic gel. Looking ahead, the company is set to enhance its manufacturing capabilities in Europe with a new high-capacity ampoule line at the Fontenay facility, expected to be operational by 2027. Furthermore, the company has secured a new Nano Drug Delivery System contract in oncology, reinforcing its position in the complex injectable space.
Shareholder Value
Reflecting the strong performance for the fiscal year, the Board of Directors has recommended a final dividend of ₹20 per equity share, subject to approval by the shareholders. This recommendation underscores the company’s commitment to delivering consistent value to its investors while maintaining a strong balance sheet with net cash of ₹31,157 million at the end of FY26.
Source: BSE
